Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 5
2010 8
2011 5
2012 4
2013 3
2014 1
2015 4
2016 1
2017 2
2018 5
2019 5
2020 3
2021 2
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. Vervoort SJ, et al. Among authors: ohlmeyer m. Cell. 2021 Jun 10;184(12):3143-3162.e32. doi: 10.1016/j.cell.2021.04.022. Epub 2021 May 17. Cell. 2021. PMID: 34004147 Free PMC article.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: ohlmeyer m. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.
Yu H, Zaveri S, Sattar Z, Schaible M, Perez Gandara B, Uddin A, McGarvey LR, Ohlmeyer M, Geraghty P. Yu H, et al. Among authors: ohlmeyer m. Medicina (Kaunas). 2023 Aug 26;59(9):1552. doi: 10.3390/medicina59091552. Medicina (Kaunas). 2023. PMID: 37763671 Free PMC article. Review.
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkönen M, von Schantz-Fant С, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J. Denisova OV, et al. Among authors: ohlmeyer m. Mol Oncol. 2023 Sep;17(9):1803-1820. doi: 10.1002/1878-0261.13488. Epub 2023 Jul 26. Mol Oncol. 2023. PMID: 37458534 Free PMC article.
Reengineered tricyclic anti-cancer agents.
Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Kastrinsky DB, et al. Among authors: ohlmeyer m. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. doi: 10.1016/j.bmc.2015.07.007. Epub 2015 Sep 11. Bioorg Med Chem. 2015. PMID: 26372073 Free PMC article.
Rapid Characterization of Solid Tumors Using Resonant Sensors.
Beierle AM, Quinn CH, Markert HR, Carr A, Marayati R, Bownes LV, Hutchins SC, Stewart JE, Hill B, Ohlmeyer M, Reuel NF, Beierle EA. Beierle AM, et al. Among authors: ohlmeyer m. ACS Omega. 2022 Sep 2;7(36):32690-32700. doi: 10.1021/acsomega.2c04345. eCollection 2022 Sep 13. ACS Omega. 2022. PMID: 36119978 Free PMC article.
Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.
Soto B, Ahmed H, Pillai M, Park SS, Ploszaj M, Reece J, Taluru H, Bobrow D, Yu H, Lafortune P, Jundi B, Costanzo L, Dabo AJ, Foronjy RF, Mueller C, Ohlmeyer M, Geraghty P. Soto B, et al. Among authors: ohlmeyer m. Am J Respir Cell Mol Biol. 2023 Nov;69(5):533-544. doi: 10.1165/rcmb.2023-0105OC. Am J Respir Cell Mol Biol. 2023. PMID: 37526463
51 results